Study of zanidatamab for HER2-positive solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your cancer has spread or cannot be removed with surgery, and you have already tried at least one prior treatment.
- Your tumor is HER2-positive (IHC 3+) as confirmed by the study's central lab.
- You have a tumor sample that can be tested for HER2.
- You have at least one measurable tumor on scans.
- You are generally well enough to be active (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.
This study looks at how patients with advanced HER2-positive stomach or gastroesophageal cancer feel and function while receiving zanidatamab as their first treatment. It aims to understand the real-world experiences and outcomes of this therapy.
This trial tests whether a targeted drug (zanidatamab, which attacks HER2-positive cancer cells) combined with chemotherapy can shrink stomach cancer before surgery, making it easier to remove. It may also help people whose cancer has spread a bit, by making it operable.
This study tests whether adding a new targeted drug called zanidatamab to standard chemotherapy before and after surgery can improve the chances of getting rid of HER2-positive stomach or esophageal cancer. It is designed for patients whose cancer can still be removed with surgery and has not spread.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.